The cardiovascular effectes of the SGLT2 inhibitors at the patients with type 2 diabetes mellitus in the real-life clinical practice: CVD-REAL trial

• Alexander S. Ametov
• Liudmila L. Kamynina
• Litvinenko V.M.

AbstractThe paper presents the information about of the multinational retrospective observational cohort CVD-REAL Trial, gave us the analysis of the use SGLT2 inhibitors in the real-life clinical practice. It was demonstrated that the popular cohort of the users of the SGLT2 inhibitors was characterized with low cardiovascular risk in the comparison with the participants of EMPA-REG OUTCOME18 with high cardiovascular risk. The CVD-REAL The trial confirmed the reduction of the hospitalization for the heart failure and the death from any case at the patients with type 2 diabetes mellitus, users of the SGLT2 inhibitors at the real-life endocrinological practice.

Keywords:type 2 diabetes mellitus, inhibitors SGLT2, EMPA-REG, dapagliflozin, canagliflozin, empagliflozin, CVD-REAL, cardiovascular risk, heart failure

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)